A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx

Business Trip, a podcast about psychedelic entrepreneurship

Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄

Episode 8 features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders.

In this episode, we discuss:

  • The science, experience, and the safety profile of ibogaine’s “neurochemical reset”

  • Navigating US drug regulatory system and securing Intellectual Property

  • Deborah’s 30 year journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approved

  • Partnership with ATAI Life Sciences

Listen to the episode here, on Spotify or Apple Podcasts.

When you’re done listening, tweet at us @businesstripfm to share your thoughts!

About Us

Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem. 

Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.

Thanks for listening,

Matias and Greg

💖 Know someone who would enjoy Business Trip?

Follow us on Twitter & Instagram.